報(bào)告題目：An Integrated Quantitative Proteomics Strategy for Systems-biology of Protein Post-translational Modification (PTM)

報(bào)告人：Dr. Zhongyi Cheng (Ph.D., CEO, PTM Biolabs, Inc.)

主持人：陳捷凱 研究員

時間：2015年7月2日10:20-11:20

地點(diǎn)：廣州生物醫(yī)藥與健康研究院A430

講座摘要：

The specific inhibitors of Protein Post-translational Modification (PTM) regulative enzymes including E3 ligase, HDAC, HMT and kinase represent promising anti-cancer drugs, while great challenges of how to effectively screen the biomarker and targets of those inhibitors still exist. Using combinative advantages of high quality PTM pan antibodies based affinity enrichment and mass spectrometer-based quantitative proteomics, the PTM substrate profile in response to the inhibitors treatment can be intensively delineated, which provides the direct impacts on biomarker and target discovery in biomedical and pharmaceutical pre-clinic studies.